摘要
目的:评价重组人表皮生长因子(rhEGF)与玻璃酸钠协同治疗白内障术后干眼症(PKPD)的有效性。方法:本研究中100例PKPD患者均来自2022年9月—2024年9月福州市第一总医院收治的的临床病例。研究采用随机数表法分组,观察组、对照组各包含50例患者。对照组以玻璃酸钠滴眼液治疗,观察组在对照组的基础上联合rhEGF治疗。评估两组在泪膜稳定性、症状消失时间、角膜上皮缺损情况、病情、泪液分泌功能、治疗有效率及不良反应方面的差异。结果:对照组的眼干涩、烧灼感、眼痛及畏光症状持续时间均长于观察组,差异有统计学意义(P<0.05)。治疗前,两组在泪膜稳定性、角膜上皮缺损情况、病情、泪液分泌功能方面,差异无统计学意义(P>0.05)。治疗后,观察组眼表疾病指数量表(OSDI)、角膜荧光素染色(FL)下降幅度大于对照组;泪液分泌实验(SIt)、泪膜破裂时间(BUT)提升幅度大于对照组,差异有统计学意义(P<0.05)。疗效评价结果表明,观察组有效率为98.00%,高于对照组的86.00%,差异有统计学意义(P<0.05)。安全性评估表明,两组在眼睑瘙痒、结膜充血及眼部红肿等局部反应的发生率上,差异无统计学意义(P>0.05)。结论:rhEGF和玻璃酸钠协同应用,可以促进PKPD患者症状消退,缓解病情,修复角膜上皮缺损,提升泪液分泌功能,延长泪膜破裂时间,疗效好,安全性高。
Objective:Evaluating the therapeutic efficacy of recombinant human epidermal growth factor(rhEGF)in synergistic combination with sodium hyaluronate for the management of post-phacoemulsification dry eye(PKPD).Method:The clinical cases of 100 PKPD patients admitted to Fuzhou First General Hospital across from September 2022 to September 2024 were selected.The study adopted the random number table method for grouping.The observation group and the control group each included 50 patients.The control group was patients treated with sodium hyaluronate eye dreps while the intervention group was treated with rhEGF on the basis of controll group.Tear film stability,the condition of corneal epithelial defect,condition,tear secretion,response rate and adverse reaction were assessed.Result:The control group exhibited significantly longer duration of ocular dryness,burning sensation,eye pain,and photophobia symptoms compared to the observation group,with statistically significant differences(P<0.05).Pretreatment assessments showed no significant intergroup differences in tear film stability,corneal epithelial defect status,disease severity,or tear secretion function(P>0.05).Post-treatment evaluations revealed significantly greater reductions in Ocular Surface Disease Index(OSDI)and fluorescein staining(FL)scores,along with more substantial improvements in Schirmer's test(SIt)and tear film breakup time(BUT)in the observation group versus controls(P<0.05).Efficacy analysis demonstrated a significantly higher treatment response rate in the observation group(98.00%)compared to the control group(86.00%)(P<0.05).Safety assessment indicated no statistically significant difference in the incidence of local reactions including eyelid itching,conjunctival congestion,and ocular redness between groups(P>0.05).Conclusion:The dual-action mechanism of rhEGF and sodium hyaluronate promotes more rapid clinical symptom abatement in affected patients,alleviate the condition,repair corneal epithelial defects,enhance tear secretion function,prolong tear film break-up time,and has good therapeutic effect and high safety.
作者
张绍斌
ZHANG Shaobin(Fuzhou First General Hospital,Fuzhou 350004,China)
出处
《中外医学研究》
2025年第26期47-50,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
白内障
超声乳化术后干眼症
重组人表皮生长因子
玻璃酸钠滴眼液
泪液分泌功能
Cataract
Post phacoemulsification dry eye syndrome
Recombinant human epidermal growth factor
Sodium hyaluronate eye drops
Tear secretion function
